Loss of synergistic transcriptional feedback loops drives diverse B-cell cancers.


Journal

EBioMedicine
ISSN: 2352-3964
Titre abrégé: EBioMedicine
Pays: Netherlands
ID NLM: 101647039

Informations de publication

Date de publication:
Sep 2021
Historique:
received: 25 05 2021
revised: 10 08 2021
accepted: 13 08 2021
pubmed: 31 8 2021
medline: 1 2 2022
entrez: 30 8 2021
Statut: ppublish

Résumé

The most common B-cell cancers, chronic lymphocytic leukemia/lymphoma (CLL), follicular and diffuse large B-cell (FL, DLBCL) lymphomas, have distinct clinical courses, yet overlapping "cell-of-origin". Dynamic changes to the epigenome are essential regulators of B-cell differentiation. Therefore, we reasoned that these distinct cancers may be driven by shared mechanisms of disruption in transcriptional circuitry. We compared purified malignant B-cells from 52 patients with normal B-cell subsets (germinal center centrocytes and centroblasts, naïve and memory B-cells) from 36 donor tonsils using >325 high-resolution molecular profiling assays for histone modifications, open chromatin (ChIP-, FAIRE-seq), transcriptome (RNA-seq), transcription factor (TF) binding, and genome copy number (microarrays). From the resulting data, we identified gains in active chromatin in enhancers/super-enhancers that likely promote unchecked B-cell receptor signaling, including one we validated near the immunoglobulin superfamily receptors FCMR and PIGR. More striking and pervasive was the profound loss of key B-cell identity TFs, tumor suppressors and their super-enhancers, including EBF1, OCT2(POU2F2), and RUNX3. Using a novel approach to identify transcriptional feedback, we showed that these core transcriptional circuitries are self-regulating. Their selective gain and loss form a complex, iterative, and interactive process that likely curbs B-cell maturation and spurs proliferation. Our study is the first to map the transcriptional circuitry of the most common blood cancers. We demonstrate that a critical subset of B-cell TFs and their cognate enhancers form self-regulatory transcriptional feedback loops whose disruption is a shared mechanism underlying these diverse subtypes of B-cell lymphoma. National Institute of Health, Siteman Cancer Center, Barnes-Jewish Hospital Foundation, Doris Duke Foundation.

Sections du résumé

BACKGROUND BACKGROUND
The most common B-cell cancers, chronic lymphocytic leukemia/lymphoma (CLL), follicular and diffuse large B-cell (FL, DLBCL) lymphomas, have distinct clinical courses, yet overlapping "cell-of-origin". Dynamic changes to the epigenome are essential regulators of B-cell differentiation. Therefore, we reasoned that these distinct cancers may be driven by shared mechanisms of disruption in transcriptional circuitry.
METHODS METHODS
We compared purified malignant B-cells from 52 patients with normal B-cell subsets (germinal center centrocytes and centroblasts, naïve and memory B-cells) from 36 donor tonsils using >325 high-resolution molecular profiling assays for histone modifications, open chromatin (ChIP-, FAIRE-seq), transcriptome (RNA-seq), transcription factor (TF) binding, and genome copy number (microarrays).
FINDINGS RESULTS
From the resulting data, we identified gains in active chromatin in enhancers/super-enhancers that likely promote unchecked B-cell receptor signaling, including one we validated near the immunoglobulin superfamily receptors FCMR and PIGR. More striking and pervasive was the profound loss of key B-cell identity TFs, tumor suppressors and their super-enhancers, including EBF1, OCT2(POU2F2), and RUNX3. Using a novel approach to identify transcriptional feedback, we showed that these core transcriptional circuitries are self-regulating. Their selective gain and loss form a complex, iterative, and interactive process that likely curbs B-cell maturation and spurs proliferation.
INTERPRETATION CONCLUSIONS
Our study is the first to map the transcriptional circuitry of the most common blood cancers. We demonstrate that a critical subset of B-cell TFs and their cognate enhancers form self-regulatory transcriptional feedback loops whose disruption is a shared mechanism underlying these diverse subtypes of B-cell lymphoma.
FUNDING BACKGROUND
National Institute of Health, Siteman Cancer Center, Barnes-Jewish Hospital Foundation, Doris Duke Foundation.

Identifiants

pubmed: 34461601
pii: S2352-3964(21)00352-2
doi: 10.1016/j.ebiom.2021.103559
pmc: PMC8403728
pii:
doi:

Substances chimiques

Biomarkers 0
Transcription Factors 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

103559

Subventions

Organisme : NCI NIH HHS
ID : R01 CA156690
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA091842
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR000448
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR002345
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA188286
Pays : United States
Organisme : NCI NIH HHS
ID : F31 CA221012
Pays : United States

Informations de copyright

Copyright © 2021 The Author(s). Published by Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare no potential conflicts of interest.

Auteurs

Jared M Andrews (JM)

Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO, USA.

Sarah C Pyfrom (SC)

Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO, USA.

Jennifer A Schmidt (JA)

Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO, USA.

Olivia I Koues (OI)

Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO, USA.

Rodney A Kowalewski (RA)

Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO, USA.

Nicholas R Grams (NR)

Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO, USA.

Jessica J Sun (JJ)

Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO, USA.

Leigh R Berman (LR)

Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO, USA.

Eric J Duncavage (EJ)

Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO, USA.

Yi-Shan Lee (YS)

Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO, USA.

Amanda F Cashen (AF)

Department of Medicine, Division of Oncology, Washington University School of Medicine, St. Louis, MO, USA.

Eugene M Oltz (EM)

Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO, USA.

Jacqueline E Payton (JE)

Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO, USA. Electronic address: jpayton@wustl.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH